170 related articles for article (PubMed ID: 34704036)
1. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
Zalles M; Smith N; Saunders D; Guzman M; Lerner M; Fung KM; Babu A; Battiste J; Chung J; Hwang K; Jin J; Towner RA
Neurooncol Adv; 2021; 3(1):vdab132. PubMed ID: 34704036
[TBL] [Abstract][Full Text] [Related]
2. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
[TBL] [Abstract][Full Text] [Related]
3. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
4. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
[TBL] [Abstract][Full Text] [Related]
5. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
[TBL] [Abstract][Full Text] [Related]
6. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
Zalles M; Smith N; Ziegler J; Saunders D; Remerowski S; Thomas L; Gulej R; Mamedova N; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Wiley G; Brown C; Battiste J; Wren JD; Towner RA
J Cell Mol Med; 2020 Jan; 24(2):1738-1749. PubMed ID: 31863639
[TBL] [Abstract][Full Text] [Related]
7. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
8. ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.
Towner RA; Smith N; Zalles M; Morris S; Toliver M; Saunders D; Lerner M; Kumar G; Axtell RC
Mult Scler Relat Disord; 2021 Apr; 49():102786. PubMed ID: 33517175
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker.
Serban F; Artene SA; Georgescu AM; Purcaru SO; Tache DE; Alexandru O; Dricu A
Onco Targets Ther; 2015; 8():3767-74. PubMed ID: 26719704
[TBL] [Abstract][Full Text] [Related]
10. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1α signaling axis.
Li J; Shen J; Wang Z; Xu H; Wang Q; Chai S; Fu P; Huang T; Anas O; Zhao H; Li J; Xiong N
Sci Rep; 2019 Sep; 9(1):13904. PubMed ID: 31554859
[TBL] [Abstract][Full Text] [Related]
11. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
[TBL] [Abstract][Full Text] [Related]
12. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma.
Serban F; Daianu O; Tataranu LG; Artene SA; Emami G; Georgescu AM; Alexandru O; Purcaru SO; Tache DE; Danciulescu MM; Sfredel V; Dricu A
J Immunoassay Immunochem; 2017; 38(1):21-33. PubMed ID: 27379831
[TBL] [Abstract][Full Text] [Related]
13. ELTD1 Promotes Gastric Cancer Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through MAPK/ERK Signaling by Regulating CSK.
Sun B; Zhong FJ
Int J Gen Med; 2021; 14():4897-4911. PubMed ID: 34475781
[TBL] [Abstract][Full Text] [Related]
14. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
Niinivirta M; Georganaki M; Enblad G; Lindskog C; Dimberg A; Ullenhag GJ
BMC Cancer; 2020 Apr; 20(1):339. PubMed ID: 32321460
[TBL] [Abstract][Full Text] [Related]
15. ELTD1-An Emerging Silent Actor in Cancer Drama Play.
Sevastre AS; Buzatu IM; Baloi C; Oprita A; Dragoi A; Tataranu LG; Alexandru O; Tudorache S; Dricu A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068040
[TBL] [Abstract][Full Text] [Related]
16. Adhesion G protein-coupled receptor, ELTD1, is a potential therapeutic target for retinoblastoma migration and invasion.
Guihurt Santiago J; Burgos-Tirado N; Lafontaine DD; Mendoza Sierra JC; Camacho RH; Vecchini Rodríguez CM; Morales-Tirado V; Flores-Otero J
BMC Cancer; 2021 Jan; 21(1):53. PubMed ID: 33430814
[TBL] [Abstract][Full Text] [Related]
17. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
18. A review of ELTD1, a pro-angiogenic adhesion GPCR.
Favara DM; Banham AH; Harris AL
Biochem Soc Trans; 2014 Dec; 42(6):1658-64. PubMed ID: 25399586
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to combat chemoresistance against glioblastomas.
Towner RA; Zalles M; Saunders D; Smith N
Cancer Drug Resist; 2020; 3(4):686-698. PubMed ID: 35582224
[TBL] [Abstract][Full Text] [Related]
20. AG488 as a therapy against gliomas.
Ziegler J; Bastian A; Lerner M; Bailey-Downs L; Saunders D; Smith N; Sutton J; Battiste JD; Ihnat MA; Gangjee A; Towner RA
Oncotarget; 2017 Sep; 8(42):71833-71844. PubMed ID: 29069750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
